Ping An Healthcare And Technology (SEHK:1833) Reported Profits, Is The Stock Fully Priced?

Ping An Healthcare and Technology (SEHK:1833) reported half year 2026 earnings with sales of CNY 2,483.83 million and net income of CNY 219.33 million, alongside basic and diluted EPS of CNY 0.10.

See our latest analysis for Ping An Healthcare and Technology.

The earnings release on 18 August has come after a weak stretch for Ping An Healthcare and Technology, with the share price at HK$6.735 and the year-to-date share price return down 53.81%, while the 3-year total shareholder return is slightly positive.

If these earnings have you considering where else growth or recovery stories could emerge in digital health, it may be worth scanning a wider set of healthcare technology stocks through the 130 healthcare AI stocks

Ping An Healthcare and Technology now trades at a steep discount to both analyst targets and some intrinsic value estimates. The key focus is where fair value really lies across that spread, and how much of the recent improvement is already priced in.

Preferred P/E of 26.4x: Is it justified?

On the latest figures, Ping An Healthcare and Technology trades on a P/E of 26.4x. That puts the HK$6.735 share price at a richer earnings multiple than both its industry and an estimated fair level.

The P/E multiple compares the current share price with earnings per share. For a healthcare platform company that has recently moved into profitability and is forecast to grow earnings by 12.7% per year, investors often watch this metric to gauge how much future profit is already reflected in the price.

According to the checks provided, the stock is considered expensive versus the estimated fair P/E of 16.4x. It is also described as expensive compared to the broader Asian Consumer Retailing industry average of 15.6x, even though it is viewed as good value relative to a narrower peer group average of 28.7x. That mix suggests the market is placing a premium on Ping An Healthcare and Technology compared with the wider sector, while still pricing it slightly below some closer peers that share similar characteristics.

Explore the SWS fair ratio for Ping An Healthcare and Technology

Result: Price-to-earnings of 26.4x (OVERVALUED)

However, Ping An Healthcare and Technology still faces risks if digital health demand softens or regulatory changes alter how its online medical and insurance services operate.

Find out about the key risks to this Ping An Healthcare and Technology narrative.

Another View on Ping An Healthcare and Technology’s Value

The P/E of 26.4x makes Ping An Healthcare and Technology look expensive next to the sector and its own fair ratio of 16.4x. Yet our DCF model points to a fair value near HK$19.82, which is well above the HK$6.74 share price. Which signal should investors pay more attention to?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ping An Healthcare and Technology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 269 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of signals around Ping An Healthcare and Technology leaves you unsure, take the time to review the full picture and consider the 1 or more rewards that analysts are optimistic about by checking the 3 key rewards.

Looking for more investment ideas beyond Ping An Healthcare and Technology?

If Ping An Healthcare and Technology has you thinking more broadly about your portfolio, do not stop here. Fresh ideas from different angles can sharpen your next move.

• Target resilient cash generators by scanning companies through the 269 high quality undervalued stocks that combine quality fundamentals with potentially attractive pricing.
• Prioritise stability and staying power with the 295 resilient stocks with low risk scores to see stocks that score well on financial strength and risk factors.
• Hunt for early opportunities before they attract wider attention using the screener containing 614 high quality undiscovered gems that focuses on financially solid but less followed stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com